Breaking News

Alligator Bioscience Trial Employs Cobra’s MaxXpress Platform

Develops cell line expressing ADC-1013 for CD40 agonistic immuno-oncology using maxXpress service platform

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cobra Biologics’ immuno-oncology antibody ADC-1013 manufactured as part of the company’s cell line development program for Alligator Bioscience, has completed its first Phase I trial.   As an essential step in the antibody production process, Cobra’s team developed the cell line expressing ADC-1013 for CD40 agonistic immuno-oncology using its maxXpress service platform to enable rapid and high-yielding production of correctly folded and glycosylated antibodies, complimented its cell based pote...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters